Skip to main content

Unmodified Bacteriophages Research Updates

 Recent research conducted by researchers from Yale University is published in Applied and Environmental Microbiology, suggesting that natural bacteriophage, or phage, can kill dysentery-causing bacteria and reduce virulence in surviving bacteria. It's a piece of inspiring news as treating dysentery has become a challenge with the rising antibiotic resistance.

 

Background

 

Shigella flexneri, the culprit causing contagious infection marked by inflammatory diarrhea and dysentery in sub-Saharan Africa and southern Asia, kills about 160,000 people globally every year. The World Health Organization (WHO) takes priority to this pathogen in terms of increasing cases, antimicrobial resistance, and limited treatment options.

 

S. flexneri is active primarily in low-income countries, like southern Asia and sub-Saharan Africa. In these places, dirty drinking water is a concern causing dysentery, while antibiotics are expensive and unavailable, not to mention the condition that the bacteria have already developed resistance to conventional antibiotics.

 

Research

 

Scientists at Yale University collected water in Cuatro Cienegas, Mexico, a region renowned for its extreme microbial biodiversity. They have successfully isolated a novel lytic phage that uses the OmpA porin of S.flexneri as a receptor. This is a natural bacteriophage named A1-1, and it can infect and break down the resistant and mutant Shigella bacteria. This study using phenotypic assays and genome sequencing has shown that this naturally occurring phage can kill Shigella flexneri and select phage-resistant mutants, including OmpA-deficient mutants and LPS-deficient mutants with reduced virulence. It demonstrates the potential benefits of phage-based therapy to fight human bacterial infections.

 

Researchers at Yale comment it as "a biomedically useful evolutionary tradeoff that improves upon standard phage therapy approaches" and hold that the A1-1 phage might even be useful for treating water sources, by selecting for avirulent S. flexneri."

 

Phage Therapy

 

Phages are viruses that infect bacteria, so they are gradually discovered as natural enemies of bacteria. The property of only attacking specific bacteria and being harmless to people, animals, and plants makes phages promising treatment, especially in the case of rising resistance to antibiotics.

 

Approaches of phage therapies include:

 

Monophage therapy using a single phage type as a therapeutic agent, which is based on a precise matching between the pathogen and the phage.

Polyphage therapy using combined phages as therapeutic agents, which can target multiple strains of a single bacterial species or multiple species.

Bio-engineered phage therapy using genetically engineered phages, which can be used to deliver therapeutic agents into target bacterial cells.

 

Unmodified Bacteriophages

 

Naturally occurring phages are unmodified or non-engineered bacteriophages. Besides applications in treating infectious diseases, they have been widely used as powerful label-free bacterial sensors for pathogen detection. Combined with innovative detector platforms showing interactions between phages and host bacteria, unmodified phages can be used to identify the natural infection cycle of phages, such as attachment to the host cell, penetration to inject nucleic acid, biosynthesis of proteins and nucleic acids, virion assembly to form the phage progeny, and host cell lysis, and the release of phage progeny.

Comments

Popular posts from this blog

Everything You Want to Know About Antibody Development

  Everything You Want to Know About Antibody Development   When foreign molecules, which are known as antigens, enter our body, antibodies will be released by B cells of the immune system to specifically bind to the antigens and finally clear out those “invaders”. Such a highly specific molecular recognition mechanism has inspired a variety of antibody development research and diagnostic applications nowadays, including IVD antibody development .   What is Antibody Development?   Antibody development is the process of creating and characterizing an antibody.   The timeline of developing antibodies starts from the injection of an antigen of interest into a host animal, so that the host’s immune system can detect it and generat e  the desired antibodies. Then, antibody development proceeds with finding and isolating the desired antibodies from the rest of the protein in sera.   The reset procedure of antibody development is varied as the desired antibodi...

An Overview of the Global Bispecific Antibody Therapeutics Market

  Antibod ies , a major component of adaptive immunity, play a critical role in protective and pathogenic immune responses. In r ecent years, a wide range of antibodies is discovered as candidates of cancer therapeutic agents, including the reconstructive molecules, bispecific antibodies (BsAbs).   About Bispecific Antibody   Bispecific antibodies, as its name indicates, consists of two antigen-binding sites, which can simultaneously bind two separate and unique antigens (or different epitopes of the same antigen). This structure is  typically designed to bind to two targets, one on a cancer cell and one on an immune cell, act ivating or redirecting immune effector cells with the goal of getting the immune cell to kill the cancer cell by antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and other cytotoxic mechanisms.   U nique biological and pharmacological properties, ...